Share on StockTwits

Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) have received a consensus recommendation of “Hold” from the eleven analysts that are presently covering the company, American Banking News.com reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $8.80.

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 7.59 on Friday. Achillion Pharmaceuticals has a 52-week low of $2.26 and a 52-week high of $8.61. The stock’s 50-day moving average is $7.23 and its 200-day moving average is $4.46. The company’s market cap is $734.7 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.74 earnings per share for the current fiscal year.

ACHN has been the subject of a number of recent research reports. Analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $5.00. Separately, analysts at Wells Fargo & Co. upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $7.36. Finally, analysts at JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday. They now have a $13.00 price target on the stock.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.